This antiviral offers new option to HIV patients

Beyzarov, Elena
August 2006
Drug Topics;8/7/2006, Vol. 150 Issue 15, p12
Trade Publication
The article features Prezista as the new protease inhibitor. Prezista is under the generic name darunavir. It is prescribed for the treatment of HIV in patients who had experienced antiretroviral treatment. It is designed to tackle viral strains that are resistant to one or more protease inhibitors. It is intended to be administered with ritonavir. Its best potency is served when given in combination with the fusion inhibitor Fuzeon. Findings on the potency of the drug meet the guidelines set by the U.S. Department of Health & Human Services, calling for suppression of HIV in patients who underwent previous treatment. It has been manufactured by Tibotec Therapeutics.


Related Articles

  • Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163 

    Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks...

  • Description of the L76V Resistance Protease Mutation in HIV-1 B and "Non-B" Subtypes. Charpentier, Charlotte; Lambert-Niclot, Sidonie; Alteri, Claudia; Storto, Alexandre; Flandre, Philippe; Svicher, Valentina; Perno, Carlo-Federico; Brun-Vézinet, Françoise; Calvez, Vincent; Marcelin, Anne-Geneviève; Ceccherini-Silberstein, Francesca; Descamps, Diane // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Objective: To describe the prevalence of the L76V protease inhibitors resistance-associated mutation (PI-RAM) in relation with patients' characteristics and protease genotypic background in HIV-1 B- and "non-B"-infected patients. Methods: Frequency of the L76V mutation between 1998 and 2010 was...

  • HIV-1 Protease Inihibitors. Eron Jr., Joseph J. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS160 

    Focuses on the role of protease inhibitors (PI) in the antiretroviral therapy for HIV-1 infected patients. Potent activity in vitro of five United States Food and Drug Administration-approved PI agents; Suppression of HIV-1 replication by PI agents with two nucleoside analogue reverse...

  • Compliance and dosage critical in HIV suppression by protease inhibition.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p377 

    Reports that starting and maintaining protease inhibitor therapy at the recommended dosages delays the development of resistant HIV virus and assists in long-term viral suppression. Presentation of indinavir (Crixivan) data.

  • Editorial Response: Discordance between Virological, Immunologic, and Clinical Outcomes of Therapy with Protease Inhibitors among Human Immunodeficiency Virus-Infected Patients. Goetz, Matthew Bidwell // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1431 

    Comments on the findings of I. Mezzaroma, M. Carlesimo, E. Pinter et al on the occurrence of discordant virological and immunologic responses among HIV-infected patients who had received protease inhibitor-based antiretroviral therapy, published in the December 1999 issue of the journal...

  • Ritonavir for advanced HIV infection.  // American Family Physician;7/1/1996, Vol. 54 Issue 1, p372 

    Reports that the United States Food and Drug Administration has approved the protease inhibitor ritonavir for the treatment of patients with human immunodeficiency virus (HIV) infection. Combination of ritonavir with nucleoside analogs or as monotherapy; Clinical trials on the efficacy of...

  • Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence. Max, Blake; Sherer, Renslow // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS96 

    Examines the therapeutic agents included in the highly active antiretroviral therapy (HAART) for the treatment of patients with HIV infections. Link between poor adherence and failure of antiretroviral therapy; Threat of short term-adverse effects to successful introduction and maintenance of...

  • Hyperlipidemia Associated with the Use of Protease Inhibitors. Smith, John H.; Martin, Gregory J.; Decker, Catherine F. // Clinical Infectious Diseases;7/1/2000, Vol. 31 Issue 1, p207 

    Comments on an article by A.D. Roberts, R.A. Muesing, D.M. Parenti, J. Hsia, A.G. Wasserman, G.L. Simon's about alterations in lipid metabolism in HIV-infected patients receiving indinavir. Development of hyperlipidemia with the use of other available protease inhibitors; Lipid profiles of the...

  • Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy.  // Clinical Infectious Diseases;5/1/2010, Vol. 50 Issue 9, p1275 

    Background. Robust long-term estimates of the risk of development of drug resistance are needed for human immunodeficiency virus (HIV)-infected patients starting combination antiretroviral therapy (cART) regimens currently used in routine clinical practice. Methods. We followed a large cohort of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics